At-a-Glance:| Company | Embrient, Inc. |
|---|
| Specialties | Tissue culture incubators |
|---|
| Mission | Embrient’s mission is to provide the most effective incubator solutions with the highest reproducibility that match physiological environments for culturing cells to advance scientific discovery. |
|---|
| Noteworthy | Embrient was founded in 2021 to carry forward the legacy of Billups-Rothenberg Inc. |
|---|
| Location | San Diego, CA |
|---|
| CEO | Kent Johnson |
|---|
Continuing the rich legacy of Billups-Rothenberg Inc. (BRI), which it acquired in 2021, Embrient, Inc. seeks to optimize reproducibility in life science research and drug discovery by providing the flagship modular incubator chamber, optimized for hypoxic tissue culture environments.
The impact of BRI's 50 years of innovations cannot be overstated. Originally founded in 1973, BRI pioneered the development of low-cost tissue culture incubators, capable of providing a full range of O2/CO2 conditions, enabling various in vitro environments. Their products are the gold standard for hypoxic experiments, used in fields such as stem cells, IVF, tumor biology, and malaria research, and are cited in thousands of peer-reviewed articles. Notably, BRI's technology played a role in Nobel Prize-winning research on HIF-1α and the control of gene regulation by oxygen levels in animal cells.
At the heart of Embrient's vision is the recognition of the critical importance of hypoxic tissue culture environments. Barry Rothenberg, one of BRI's founding members who remains actively involved in Embrient's operations, has long championed the significance of modeling tissue culture conditions in hypoxic settings that most accurately reflect in situ environments.
By combining its historical expertise with cutting-edge innovation and a strong focus on reproducibility, Embrient is well-positioned to make significant contributions to the field of cell culture technology and, by extension, to the broader landscape of life science research and drug discovery.